Axonics Modulation Technologies (NSDQ:AXNX) said today that the underwriters behinds its $120 million initial public offering exercised their over-allotment option, adding another $18 million to its coffers.
Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, said the underwriters picked up 1.2 million shares at $15 each, taking gross proceeds from the flotation to $138 million.
Axonics closed the IPO Nov. 2, after first setting a range of $93.3 million to $106.7 million which it later increased to $120 million.
Axonics touts the r-SNM device as the first such rechargeable system; it’s designed to deliver mild electrical stimulation using a four-electrode lead introduced through the sacrum and a pulse generator implanted in the upped buttocks. It won CE Mark approval in the European Union in June 2016; an external trial module won an FDA nod last July. It’s also approved for market in Canada and Australia. In its initial IPO filing, Axonics said it expects to file a pre-market approval bid with the FDA during the first quarter next year.
BofA Merrill Lynch and Morgan Stanley were joint book-runners, with Wells Fargo Securities as lead manager and SunTrust Robinson Humphrey as co-manager, Axonics said.
AXNX shares opened at $16.05 apiece on Oct. 31 before closing down -6.7% at $14.98.
The stock was trading at $15.12 per share today in early-afternoon activity, up 0.5%.
DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry.
Use code LASTCHANCE to save an additional 20%.